Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis

Lancet

Volumn 335, Issue 8697, 1990, Pages 1051-1055

  Tugwell, Peter ^a,c   Bombardier, Claire ^b   Gent, Michael ^c   Bennett, Kathryn J ^c   Bensen, William G ^d   Carette, Simon ^e   Chalmers, Andrew ^f   Esdaile, John M ^g   Klinkhoff, Alice V ^f   Kraag, Gunnar R ^h   Ludwin, David ^c   Roberts, Robin S ^c  

^a Children's Hospital at Chedoke McMaster   (United States)

^b WELLESLEY HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ST JOSEPH S HOSPITAL   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g MONTREAL GENERAL HOSPITAL   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; PLACEBO;

ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ARTHRITIS, RHEUMATOID; BLOOD PRESSURE; CREATININE; CYCLOSPORINS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; MULTICENTER STUDIES; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SUPPORT, NON-U.S. GOV'T;

EID: 0025265635     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Amor B, Herson D, Cherot A, Delbarre F. Polyarthritis rhumatoides evoluant depuis plus de 10 ans (1966-1978): analyse de l'evolution et des traitements de 100 ans. Ann Med Interne (Paris) 1981; 132: 168-73.
2. Zatarain E, Williams CA, Fries JF. Comparison of adverse reactions of methotrexate and other disease-modifying agents. Arthritis Rheum 1988; 31: S116.
3. Pincus T, Callahan LF. Methotrexate is significantly more likely to be continued over two years than gold salts, penicillamine or hydroxychloroquin in rheumatoid arthritis. Arthritis Rheum 1989; 32: S128.
4. Van Rijthoven A, Dijkmans B, Goeithe H, et al. Cyclosporin treatment for rheumatoid arthritis: a placebo c ontrolled double blind multicentre study. Ann Rheum Dis 1986; 45: 726-41.
5. Beng KJ, Forre O, Bjerkhack F, et al. Side effects of cyclosporine A: treatment in patients with rheumatoid arthritis. Kidney Int 1986; 29: 1180-87.
6. Weinblatt ME, Coblyn JS, Fraser PA. Cyclosporine: a treatment of refractory rheumatoid arthritis. Arthritis Rheum 1987; 30: 11-17.
7. Forre O, Bjerkhoel F, Salvesem CF, et al. An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 1987; 30: 88-92.
8. Dougados M, Awada H, Amor B. Cyclosporine in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988; 47: 127-33.
9. Yocum DE, Klippel JH, Wilder RL, et al. Cyclosporine A in severe, treatment-refractory rheumatoid arthritis. Ann Intern Med 1988; 109: 863-69.
10. Tugwell P, Bombardier C, Gent M, et al. Low dose cyclosporine in rheumatoid arthritis: a pilot study. J Rheumatol 1987; 14: 1108-14.
11. Donatsch P, Abisch E, Homberger M, et al. A radioimmunoassay to measure cyclosporine in plasma and serum samples. J Immunoassay 1982; 2: 19-32.
12. Klinkhoff A, Bellamy N, Bombardier C, et al. An experiment in reducing observer variability of the examination for joint tenderness. J Rheumatol 1988; 15: 492-94.
13. Huskisson EC. Measurement of pain. J Rheumatol 1982; 5: 768-69.
14. Tugwell P, Bombardier C, Buchanan WW, et al. Impact of methotrexate upon quality of life in rheumatoid arthritis assessed by traditional standard items and individualised patient preference health status questionnaires. Arch Intern Med 1990; 150: 59-62.
15. Buchanan WW, Tugwell P. Clinical evaluation in rheumatic diseases. In: McCarty DJ, ed. Arthritis and allied health conditions, 10th ed. Philadelphia: Leo Febiger, 1985: 156-75.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
17. Clark P, Tugwell P, Bennett K, Bombardier C. Meta-analysis of injectable gold in rheumatoid arthritis. J Rheumatol 1989; 16: 442-446.
18. Tugwell P, Bennett K, Gent M. Methotrexate in rheumatoid arthritis. Ann Intern Med 1987; 107: 358-66.
19. Multicentre trial group. Controlled trial of D-penicillamine in severe rheumatoid arthritis. Lancet 1973; i: 275-80.
20. Jaffe IA. The technique of penicillamine administration in rheumatoid arthritis. Arthritis Rheum 1975; 18: 513-14.
21. Palestine AR, Nussenblatt RB, Chan C-C. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 1984; 77: 652-56.
22. Ludwin D, Bennett KJ, Grace EM, et al. Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine. Transpl Proc 1988; XX (suppl 4): 367-70.
23. Levey A, Perrone RD, Madias NE. Serum creatinine and renal function. Ann Rev Med 1988; 39: 465-90.
24. Gabriel R. Time to scrap creatinine clearance? Br Med J 1986; 293: 1370-73.
25. Ponticelli C, Zucchelli P, Passerini P, et al. A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 1989; 320: 8-13.
26. Pitty MH. Safety of long term cyclosporine therapy in rheumatoid arthritis. ILAR '89 Proceedings. São Paulo. Companhia Melhoramentos de São Paulo, 1989: 491-92.
27. Tugwell P, Bennett KJ, Bell M, Gent M. Methotrexate in rheumatoid arthritis: feedback on American College of Physicians guidelines. Ann Intern Med 1989; 110: 581-83.
28. Pincus T, Callahan LF, Vaughn WK. Questionnaire, walking time, and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987; 14: 240-51.
29. Mitchell DM, Spitz PW, Young DY, et al. Survival, prognosis and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706-14.
30. Tiliakos NA. Low-dose cytotoxic drug combination therapy in intractable rheumatoid arthritis. Arthritis Rheum 1986; 29: 579.